Executive Summary The Swiss health care products agency said the digital platforms it was building for processes relating to approvals, authorizations and market surveillance aimed to make data management faster and more targeted. You may also be interested in… New EU Approvals The Pink Sheet’s list of EU centralized approvals of new active substances has been updated to add a new product – Vafseo, Akebia Therapeutics’ treatment for symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis. NICE, CADTH and ICER say they have taken a step toward greater transparency of unpublished data and a tangible outcome resulting from cooperation among global health technology assessment bodies. This is an update of recommendations from the European Medicines Agency’s Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP. Swissmedic is building a digital corporate solution Source: Shutterstock
Click here to view original web page at pink.pharmaintelligence.informa.com
